10:15 AM EST - Fennec Pharmaceuticals Inc. : Today announced the initiation of an investigator-sponsored study by University of Arizona Cancer Center to evaluate use of PEDMARK® (sodium thiosulfate injection) in adolescent and young adult (AYA) and adult patients with head and neck and testicular cancers receiving cisplatin. Fennec Pharmaceuticals Inc.
shares T.FRX are trading unchanged at $8.93.
